

Brian Lee Claggett

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4414334/brian-lee-claggett-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

255
papers

13,643
citations

56
h-index

111
g-index

300
ext. papers

18,580
ext. citations

10
avg, IF

6.32
L-index

#	Paper	IF	Citations
255	Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart Failure.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 355-368	15.1	1
254	Early B-Type Natriuretic Peptide Change in HFrEF Patients Treated With Sacubitril/Valsartan: A Pooled Analysis of EVALUATE-HF and PROVE-HF.. <i>JACC: Heart Failure</i> , 2022 , 10, 119-128	7.9	1
253	Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study.. <i>Journal of the American Heart Association</i> , 2022 , e021715	6	0
252	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure.. <i>Circulation</i> , 2022 ,	16.7	7
251	Cardiac Structure and Function and Diabetes-Related Risk of Death or Heart Failure in Older Adults.. <i>Journal of the American Heart Association</i> , 2022 , e022308	6	1
250	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.. <i>JACC: Heart Failure</i> , 2022 , 10, 336-346	7.9	0
249	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes.. <i>Journal of the American Heart Association</i> , 2022 , e021327	6	1
248	Association of Left Atrial Structure and Function With Heart Failure in Older Adults.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1549-1561	15.1	1
247	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARIC-NCS.. <i>Journal of the American Heart Association</i> , 2022 , 11, e024292	6	0
246	Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis. <i>BMJ Open</i> , 2022 , 12, e059994	3	2
245	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. <i>Circulation</i> , 2021 ,	16.7	5
244	Choosing clinically interpretable summary measures and robust analytic procedures for quantifying the treatment difference in comparative clinical studies. <i>Statistics in Medicine</i> , 2021 , 40, 6235-6242	2.3	1
243	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021 , 10, e021494	6	0
242	Angiotensin Receptor-Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021 , 385, 1845-1855	59.2	21
241	Depressive Symptoms, Cardiac Structure and Function, and Risk of Incident Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction in Late Life. <i>Journal of the American Heart Association</i> , 2021 , 10, e020094	6	1
240	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021 , 14, e008293	7.6	2
239	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 ,	16.2	9

238	Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1211-1221	15.1	1
237	Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex. <i>Circulation: Heart Failure</i> , 2021 , 14, e007891	7.6	3
236	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis. <i>Circulation: Heart Failure</i> , 2021 , 14, e008052	7.6	4
235	Temporal variations in the severity of COVID-19 illness by race and ethnicity. <i>BMJ Nutrition, Prevention and Health</i> , 2021 , 4, 166-173	6.7	1
234	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021 , 23, 1040-1048	12.3	29
233	Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. <i>JAMA Cardiology</i> , 2021 , 6, 509-520	16.2	7
232	The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). <i>European Journal of Heart Failure</i> , 2021 , 23, 1052-1056	12.3	4
231	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 386-397	7.9	2
230	Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy. <i>American Journal of Gastroenterology</i> , 2021 , 116, 1638-1645	0.7	4
229	A-lines and B-lines in patients with acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 909-917	4.3	2
228	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1217-1225	12.3	39
227	Influence of study discontinuation during the run-in period on the estimated efficacy of sacubitril/valsartan in the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	2
226	Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. <i>European Journal of Heart Failure</i> , 2021 , 23, 1290-1295	12.3	5
225	Heart failure associated with imported malaria: a nationwide Danish cohort study. <i>ESC Heart Failure</i> , 2021 , 8, 3521-3529	3.7	1
224	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1298-1305	16.2	2
223	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. <i>Circulation</i> , 2021 , 144, 177-189	16.9	5
222	Mid- to Late-Life Inflammation and Risk of Cardiac Dysfunction, HFpEF and HFrEF in Late Life. <i>Journal of Cardiac Failure</i> , 2021 , 27, 1382-1392	3.3	0
221	Combining diastolic dysfunction and natriuretic peptides to risk stratify patients with heart failure with reduced ejection fraction. <i>International Journal of Cardiology</i> , 2021 , 335, 59-65	3.2	0

220	Epithelial Cell Biomarkers Are Predictive of Response to Biologic Agents in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 677-685	4.5	1
219	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 39-49	27.4	22
218	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 13-24	7.9	10
217	Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes. <i>Circulation</i> , 2021 , 143, 761-763	16.7	30
216	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021 , 77, 546-556	8.5	7
215	Sex differences in congestive markers in patients hospitalized for acute heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 1784-1795	3.7	2
214	Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. <i>Circulation</i> , 2021 , 144, e70-e91	16.7	5
213	Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 89-91	15.1	2
212	Prognostic Value of Minimal Left Atrial Volume in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021 , 10, e019545	6	3
211	Excess mortality in solid organ transplant recipients hospitalized with COVID-19: A large-scale comparison of SOT recipients hospitalized with or without COVID-19. <i>Clinical Transplantation</i> , 2021 , e14492	2.8	4
210	Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial. <i>JACC: Heart Failure</i> , 2021 , 9, 627-635	7.9	1
209	Associations of Insulin Resistance With Systolic and Diastolic Blood Pressure: A Study From the HCHS/SOL. <i>Hypertension</i> , 2021 , 78, 716-725	8.5	0
208	Mucosal Biomarker of Innate Immune Activation Predicts Response to Vedolizumab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 1554-1561	4.5	5
207	Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1662-1671	12.3	17
206	Mid- to Late-Life Time-Averaged Cumulative Blood Pressure and Late-Life Cardiac Structure, Function, and Heart Failure. <i>Hypertension</i> , 2020 , 76, 808-818	8.5	5
205	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. <i>European Journal of Heart Failure</i> , 2020 , 22, 1133-1143	12.3	8
204	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020 , 6, 315-322	4.6	11
203	Body mass index and B-lines on lung ultrasonography in chronic and acute heart failure. <i>ESC Heart Failure</i> , 2020 , 7, 1201-1209	3.7	10

202	Quantification of pleural effusions on thoracic ultrasound in acute heart failure. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020 , 9, 513-521	4.3	3
201	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis. <i>PLoS Medicine</i> , 2020 , 17, e1003361	11.6	3
200	Postsystolic shortening on echocardiography as a gateway to cardiac computed tomography in patients with suspected stable angina pectoris. <i>International Journal of Cardiovascular Imaging</i> , 2020 , 36, 309-316	2.5	4
199	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Circulation</i> , 2020 , 141, 338-351	16.7	122
198	Impact on survival of combination inhalers in patients with COPD at high risk of cardiovascular events. <i>International Journal of Cardiology</i> , 2020 , 300, 237-244	3.2	2
197	Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. <i>Circulation</i> , 2020 , 142, 2080-2082	16.7	66
196	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. <i>JACC: Heart Failure</i> , 2020 , 8, 844-855	7.9	18
195	Myocardial performance index is associated with cardiac computed tomography findings in patients with suspected coronary artery disease. <i>Echocardiography</i> , 2020 , 37, 1741-1748	1.5	
194	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 175	8.7	1
193	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. <i>Diabetes Care</i> , 2020 , 43, 2226-2233	14.6	9
192	Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. <i>Circulation: Heart Failure</i> , 2020 , 13, e008007	7.6	1
191	Associations Between Depressive Symptoms and HFpEF-Related Outcomes. <i>JACC: Heart Failure</i> , 2020 , 8, 1009-1020	7.9	6
190	Angiotensin-Nepriylsin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation</i> , 2020 , 142, 1236-1245	16.7	32
189	Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death. <i>Europace</i> , 2020 , 22, 74-83	3.9	6
188	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
187	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
186	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
185	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		

184	Pulmonary vascular dysfunction among people aged over 65 years in the community in the Atherosclerosis Risk In Communities (ARIC) Study: A cross-sectional analysis 2020 , 17, e1003361		
183	Association Between Circulating Troponin Concentrations, Left Ventricular Systolic and Diastolic Functions, and Incident Heart Failure in Older Adults. <i>JAMA Cardiology</i> , 2019 , 4, 997-1006	16.2	20
182	Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1609-1620	59.2	705
181	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF. <i>Circulation</i> , 2019 , 140, 1369-1379	16.7	28
180	Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. <i>JACC: Heart Failure</i> , 2019 , 7, 849-858	7.9	65
179	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1199-1208	6.7	51
178	Association of Undifferentiated Dyspnea in Late Life With Cardiovascular and Noncardiovascular Dysfunction: A Cross-sectional Analysis From the ARIC Study. <i>JAMA Network Open</i> , 2019 , 2, e195321	10.4	8
177	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019 , 12, e006125	7.6	10
176	Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 483-490	7.4	5
175	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1264-1272	15.1	79
174	Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2019 , 4, 363-369	16.2	61
173	Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study. <i>JAMA Cardiology</i> , 2019 , 4, 466-472	16.2	40
172	Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. <i>JAMA Surgery</i> , 2019 , 154, 466-467	5.4	1
171	Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 795-806	15.1	82
170	Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 337-341	12.3	69
169	Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy. <i>Heart</i> , 2019 , 105, 34-41	5.1	19
168	Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases. <i>Therapeutic Innovation and Regulatory Science</i> , 2019 , 53, 387-397	1.2	4
167	Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 1129-1141	12.3	10

166	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019 , 7, 664-675	7.9	28
165	Longitudinal Associations Between Income Changes and Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2019 , 4, 1203-1212	16.2	15
164	Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2858-2873	15.1	55
163	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019 , 7, 1022-1028	7.9	2
162	Left atrial structure and function and the risk of death or heart failure in atrial fibrillation. <i>European Journal of Heart Failure</i> , 2019 , 21, 1571-1579	12.3	21
161	Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. <i>JACC: Heart Failure</i> , 2019 , 7, 25-32	7.9	32
160	Treatment of Anemia With Darbeoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019 , 73, 309-315	7.4	15
159	HFE H63D Polymorphism and the Risk for Systemic Hypertension, Myocardial Remodeling, and Adverse Cardiovascular Events in the ARIC Study. <i>Hypertension</i> , 2019 , 73, 68-74	8.5	2
158	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , 2019 , 139, 422-423	16.7	
157	The 3A3B score: The simple risk score for heart failure with preserved ejection fraction - A report from the CHART-2 Study. <i>International Journal of Cardiology</i> , 2019 , 284, 42-49	3.2	11
156	Machine learning-based phenotyping in heart failure to identify responders to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2019 , 21, 74-85	12.3	90
155	Influenza Vaccine in Heart Failure. <i>Circulation</i> , 2019 , 139, 575-586	16.7	67
154	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019 , 123, 611-617	3	14
153	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018 , 11, 1-7	2.5	3
152	Towards personalized therapy for multiple sclerosis: limitations of observational data. <i>Brain</i> , 2018 , 141, e38	11.2	4
151	Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2018 , 6, 547-554	18.1	89
150	When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data Interpretation. <i>Circulation: Heart Failure</i> , 2018 , 11, e005116	7.6	1
149	Adiposity, body composition and ventricular-arterial stiffness in the elderly: the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2018 , 20, 1191-1201	12.3	22

148	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 489-498	7.9	138
147	Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e004457	7.6	34
146	Defining Study Outcomes That Better Reflect Individual Response to Treatment. <i>Pediatric Infectious Disease Journal</i> , 2018 , 37, 258-262	3.4	4
145	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , 2018 , 20, 1230-1239	12.3	159
144	Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study. <i>JAMA Cardiology</i> , 2018 , 3, 200-206	16.2	28
143	Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction. <i>American Journal of Hypertension</i> , 2018 , 31, 407-414	2.3	20
142	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018 , 138, 570-577	16.7	38
141	Lack of Association Between Heart Failure and Incident Cancer. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1501-1510	15.1	27
140	Widening Racial Differences in Risks for Coronary Heart Disease. <i>Circulation</i> , 2018 , 137, 1195-1197	16.7	11
139	Estimating Treatment Effect With Clinical Interpretation From a Comparative Clinical Trial With an End Point Subject to Competing Risks. <i>JAMA Cardiology</i> , 2018 , 3, 357-358	16.2	16
138	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018 , 6, 564-569	7.9	18
137	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018 , 11, e004457	7.6	20
136	Trajectories of Blood Pressure Elevation Preceding Hypertension Onset: An Analysis of the Framingham Heart Study Original Cohort. <i>JAMA Cardiology</i> , 2018 , 3, 427-431	16.2	18
135	Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial. <i>Journal of Cardiac Failure</i> , 2018 , 24, 313-320	3.3	33
134	Influence of ejection fraction on cause-specific mortality in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018 , 20, 815-816	12.3	5
133	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , 2018 , 131, 165-172	2.4	22
132	Left ventricular ejection time is an independent predictor of incident heart failure in a community-based cohort. <i>European Journal of Heart Failure</i> , 2018 , 20, 1106-1114	12.3	29
131	Quantifying the totality of treatment effect with multiple event-time observations in the presence of a terminal event from a comparative clinical study. <i>Statistics in Medicine</i> , 2018 , 37, 3589-3598	2.3	7

130	The Reply. <i>American Journal of Medicine</i> , 2018 , 131, e349-e351	2.4	0
129	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial. <i>JACC: Heart Failure</i> , 2018 , 6, 689-697	7.9	36
128	Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). <i>Circulation: Heart Failure</i> , 2018 , 11, e004446	7.6	37
127	Declining Lung Function and Cardiovascular Risk: The ARIC Study. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1109-1122	15.1	30
126	Sex as a predictor of response to cancer immunotherapy. <i>Lancet Oncology, The</i> , 2018 , 19, e377	21.7	0
125	Right Ventricular Function, Right Ventricular-Pulmonary Artery Coupling, and Heart Failure Risk in 4 US Communities: The Atherosclerosis Risk in Communities (ARIC) Study. <i>JAMA Cardiology</i> , 2018 , 3, 939-948	16.2	46
124	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018 , 11, 155-164	2.5	13
123	Dietary carbohydrate intake and mortality: a prospective cohort study and meta-analysis. <i>Lancet Public Health, The</i> , 2018 , 3, e419-e428	22.4	294
122	Meta-analysis to Evaluate High-Dose Therapy Followed by Stem Cell Transplant in Patients With Multiple Myeloma. <i>JAMA Oncology</i> , 2018 , 4, 1617-1618	13.4	1
121	Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trial. <i>Diabetologia</i> , 2018 , 61, 581-588	10.3	10
120	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 504-510	12.3	37
119	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 483-490	12.3	17
118	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. <i>Journal of Diabetes Research</i> , 2018 , 2018, 1631263	3.9	13
117	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018 , 11, e005288	7.6	23
116	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. <i>Circulation</i> , 2018 , 138, 1599-1601	16.7	16
115	Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 1763-1773	15.1	34
114	Caffeine Consumption and Mortality in Diabetes: An Analysis of NHANES 1999-2010. <i>Frontiers in Endocrinology</i> , 2018 , 9, 547	5.7	13
113	IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2018 , 11, e005133	7.6	16

112	The frailty syndrome and outcomes in the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1570-1577	21.5	56
111	Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 1701-1709	12.3	34
110	Visualization, Quantification, and Alignment of Spectral Drift in Population Scale Untargeted Metabolomics Data. <i>Analytical Chemistry</i> , 2017 , 89, 1399-1404	7.8	29
109	Race-Related Differences in Left Ventricular Structural and Functional Remodeling in Response to Increased Afterload: The ARIC Study. <i>JACC: Heart Failure</i> , 2017 , 5, 157-165	7.9	24
108	Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. <i>New England Journal of Medicine</i> , 2017 , 376, 1690-1692	59.2	135
107	Left atrial structure and function in cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2017 , 18, 1128-1137	4.1	50
106	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). <i>Circulation</i> , 2017 , 136, 982-992	16.7	55
105	Racial Disparities in Risks of Stroke. <i>New England Journal of Medicine</i> , 2017 , 376, 2089-2090	59.2	12
104	Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	45
103	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 522-531	7.4	7
102	An Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	26
101	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017 , 19, 1043-1052	12.3	22
100	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. <i>JACC: Heart Failure</i> , 2017 , 5, 241-252	7.9	90
99	Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 333-340	18.1	164
98	Contemporary Assessment of Left Ventricular Diastolic Function in Older Adults: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2017 , 135, 426-439	16.7	63
97	Regional Longitudinal Deformation Improves Prediction of Ventricular Tachyarrhythmias in Patients With Heart Failure With Reduced Ejection Fraction: A MADIT-CRT Substudy (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). <i>Circulation: Cardiovascular Imaging</i> , 2017 , 10,	3.9	18
96	The Myth of Making Inferences for an Overall Treatment Efficacy with Data from Multiple Comparative Studies Via Meta-Analysis. <i>Statistics in Biosciences</i> , 2017 , 9, 284-297	1.5	6
95	Ferritin levels and risk of heart failure-the Atherosclerosis Risk in Communities Study. <i>European Journal of Heart Failure</i> , 2017 , 19, 340-347	12.3	24

94	Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. <i>JAMA Oncology</i> , 2017 , 3, 1692-1696	13.4	113
93	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study. <i>JACC: Heart Failure</i> , 2017 , 5, 782-791	7.9	18
92	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2017 , 136, 1560-1562	16.7	5
91	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. <i>JACC: Heart Failure</i> , 2017 , 5, 591-599	7.9	10
90	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017 , 46, 488-497	4.6	5
89	Prognostic Value of Cardiopulmonary Exercise Testing in Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	55
88	Sacubitril/valsartan in PARADIGM-HF - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 496	18.1	
87	Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. <i>JAMA Cardiology</i> , 2017 , 2, 79-85	16.2	84
86	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. <i>European Journal of Heart Failure</i> , 2017 , 19, 792-799	12.3	28
85	Heart Failure Stages Among Older Adults in the Community: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2017 , 135, 224-240	16.7	86
84	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017 , 10, 233-242	2.5	3
83	Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events. <i>Blood</i> , 2017 , 130, 685-685	2.2	2
82	Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities). <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	43
81	Smoking and Cardiac Structure and Function in the Elderly: The ARIC Study (Atherosclerosis Risk in Communities). <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9, e004950	3.9	38
80	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016 , 68, 873-881	7.4	21
79	Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. <i>European Journal of Heart Failure</i> , 2016 , 18, 1238-1243	12.3	44
78	Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	35
77	Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2016 , 1, 666-72	16.2	86

76	A predictive enrichment procedure to identify potential responders to a new therapy for randomized, comparative controlled clinical studies. <i>Biometrics</i> , 2016 , 72, 877-87	1.8	25
75	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016 , 37, 455-62	9.5	217
74	Prehypertension is Associated With Abnormalities of Cardiac Structure and Function in the Atherosclerosis Risk in Communities Study. <i>American Journal of Hypertension</i> , 2016 , 29, 568-74	2.3	34
73	Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2016 , 374, 1095-6	59.2	42
72	Left Atrial Structure and Function Across the Spectrum of Cardiovascular Risk in the Elderly: The Atherosclerosis Risk in Communities Study. <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9, e004010	3.9	18
71	A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2016 , 62, 873-8 ⁸	2.8	10
70	Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e002744	7.6	100
69	Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. <i>Circulation: Heart Failure</i> , 2016 , 9, e001937	7.6	47
68	Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 152-158	7.9	73
67	Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study. <i>Diabetes Care</i> , 2016 , 39, 677-85	14.6	32
66	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. <i>European Heart Journal</i> , 2016 , 37, 466-72	9.5	22
65	Influence of cigarette smoking on cardiac biomarkers: the Atherosclerosis Risk in Communities (ARIC) Study. <i>European Journal of Heart Failure</i> , 2016 , 18, 629-37	12.3	24
64	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016 , 5,	6	17
63	Efficacy of Sacubitril/Valsartan Relative to Prior Decompensation: The PARADIGM-HF Trial. <i>JACC: Heart Failure</i> , 2016 , 4, 816-822	7.9	58
62	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016 , 9, e002763	7.6	147
61	Cardiac structure and function and leisure-time physical activity in the elderly: The Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2016 , 37, 2544-51	9.5	20
60	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016 , 29, 537-44	5.8	22
59	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1895-902	4	7

58	Retinal Vessel Calibers in Predicting Long-Term Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2016 , 134, 1328-1338	16.7	121
57	Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , 2016 , 18, 1228-1234	12.3	118
56	On the restricted mean survival time curve in survival analysis. <i>Biometrics</i> , 2016 , 72, 215-21	1.8	119
55	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. <i>European Heart Journal</i> , 2015 , 36, 939-45	9.5	62
54	Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015 , 17, 510-7	12.3	115
53	Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>European Journal of Heart Failure</i> , 2015 , 17, 301-12	12.3	37
52	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015 , 132, 402-14	16.7	263
51	Relationship between alcohol consumption and cardiac structure and function in the elderly: the Atherosclerosis Risk In Communities Study. <i>Circulation: Cardiovascular Imaging</i> , 2015 , 8,	3.9	28
50	Efficacy of LCZ696 Persists at Lower Than Target Doses in the PARADIGM-HF Trial. <i>Journal of Cardiac Failure</i> , 2015 , 21, S9-S10	3.3	6
49	Sex-Specific Association of Sleep Apnea Severity With Subclinical Myocardial Injury, Ventricular Hypertrophy, and Heart Failure Risk in a Community-Dwelling Cohort: The Atherosclerosis Risk in Communities-Sleep Heart Health Study. <i>Circulation</i> , 2015 , 132, 1329-37	16.7	94
48	Right Atrial Function in Pulmonary Arterial Hypertension. <i>Circulation: Cardiovascular Imaging</i> , 2015 , 8, e003521; discussion e003521	3.9	58
47	Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study. <i>Circulation: Heart Failure</i> , 2015 , 8, 448-54	7.6	47
46	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015 , 8, 1052-8	7.6	54
45	Ideal Cardiovascular Health During Adult Life and Cardiovascular Structure and Function Among the Elderly. <i>Circulation</i> , 2015 , 132, 1979-89	16.7	38
44	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015 , 373, 2247-57	59.2	1393
43	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , 2015 , 36, 669-75	9.5	47
42	Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension. <i>European Journal of Heart Failure</i> , 2015 , 17, 63-73	12.3	16
41	Response to Letter Regarding Article, Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study. <i>Circulation: Heart Failure</i> , 2015 , 8, 1010	7.6	

40	A versatile test for equality of two survival functions based on weighted differences of Kaplan-Meier curves. <i>Statistics in Medicine</i> , 2015 , 34, 3680-95	2.3	17
39	Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. <i>European Heart Journal</i> , 2015 , 36, 1990-7	9.5	245
38	Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. <i>Annals of Internal Medicine</i> , 2015 , 163, 127-34	8	122
37	Treatment selections using risk-benefit profiles based on data from comparative randomized clinical trials with multiple endpoints. <i>Biostatistics</i> , 2015 , 16, 60-72	3.7	30
36	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015 , 169, 631-638.e7	4.9	72
35	Distinct neural representations of placebo and nocebo effects. <i>NeuroImage</i> , 2015 , 112, 197-207	7.9	73
34	Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2015 , 66, 429-40	7.4	20
33	Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. <i>New England Journal of Medicine</i> , 2015 , 373, 2289-90	59.2	71
32	Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	40
31	The amyloidogenic V122I transthyretin variant in elderly black Americans. <i>New England Journal of Medicine</i> , 2015 , 372, 21-9	59.2	136
30	Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. <i>Circulation</i> , 2015 , 131, 34-42	16.7	534
29	Spirolactone for heart failure with preserved ejection fraction. <i>New England Journal of Medicine</i> , 2014 , 370, 1383-92	59.2	1365
28	Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 447-56	15.1	439
27	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial. <i>European Journal of Heart Failure</i> , 2014 , 16, 671-7	12.3	56
26	Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 42-7	9.5	48
25	Temporal trends in the population attributable risk for cardiovascular disease: the Atherosclerosis Risk in Communities Study. <i>Circulation</i> , 2014 , 130, 820-8	16.7	100
24	Reply: does speckle tracking really improve diagnosis and risk stratification in patients with HF with normal EF?. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1535-6	15.1	
23	Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities). <i>JACC: Heart Failure</i> , 2014 , 2, 447-54	7.9	32

22	Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 590-5	7.6	97
21	Meta-Analysis With Fixed, Unknown, Study-Specific Parameters. <i>Journal of the American Statistical Association</i> , 2014 , 109, 1660-1671	2.8	17
20	Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2380-5	2.2	327
19	Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2014 , 35, 3442-51	9.5	54
18	Reply from the authors. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014 , 189, 869-70	10.2	
17	Impaired left atrial function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 1096-103	12.3	150
16	Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014 , 16, 535-42	12.3	137
15	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 895-902	7.6	25
14	Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation: Heart Failure</i> , 2014 , 7, 740-51	7.6	159
13	Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. <i>Circulation: Heart Failure</i> , 2014 , 7, 573-9	7.6	112
12	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 372-81	5.8	19
11	Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities). <i>JACC: Heart Failure</i> , 2013 , 1, 531-6	7.9	44
10	Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). <i>Gastrointestinal Endoscopy</i> , 2013 , 77, 624-30	5.2	40
9	Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1460-5	10.2	61
8	Race influences the safety and efficacy of spironolactone in severe heart failure. <i>Circulation: Heart Failure</i> , 2013 , 6, 970-6	7.6	27
7	Differential influence of distinct components of increased blood pressure on cardiovascular outcomes: from the atherosclerosis risk in communities study. <i>Hypertension</i> , 2013 , 62, 492-8	8.5	9
6	EFFECTIVELY SELECTING A TARGET POPULATION FOR A FUTURE COMPARATIVE STUDY. <i>Journal of the American Statistical Association</i> , 2013 , 108, 527-539	2.8	84
5	Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association. <i>PLoS ONE</i> , 2013 , 8, e67485	3.7	62

4	Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. <i>European Heart Journal</i> , 2012 , 33, 1137-41	9.5	54
3	Increased epithelial gaps in the small intestine are predictive of hospitalization and surgery in patients with inflammatory bowel disease. <i>Clinical and Translational Gastroenterology</i> , 2012 , 3, e19	4.2	35
2	Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. <i>Gastrointestinal Endoscopy</i> , 2011 , 73, 1174-80	5.2	60
1	Left atrial inflow propagation velocity derived by color M-mode Doppler in acute heart failure. <i>International Journal of Cardiovascular Imaging</i> , 1		